Dec. 7 at 1:31 PM
$FMS ,
$NVS ,
$TPST :
We already know what good early indications are for TPST-1120 against nasty Chronic Kidney Disease. More PreClinicals and Phase One combined with a CAR-T could well be worth it. Please, do your Due Diligence.
How CAR-T is being explored for CKD:
Targeting Fibrosis: Researchers are developing CAR-T cells to target Platelet-Derived Growth Factor Receptor beta (PDGFRβ), a marker on cells that produce the excess matrix (ECM) causing fibrosis, a hallmark of CKD.
Alleviating Pathology: Studies in mouse models show PDGFRβ CAR-T cells significantly reduce fibrosis and associated kidney damage, with no observed toxicity, and even show promise in human kidney organoids.
Autoimmune Kidney Diseases (AIKDs): CAR-T cells targeting B cells (like anti-CD19 CAR-T) are showing success in depleting autoreactive B cells, reducing immune complex deposition, and calming inflammation in AIKDs, essentially resetting the immune system.
Thanks, Microsoft Bing CoPilot.
